Abstract | BACKGROUND: METHODS: RESULTS: We calculated that, on average, 30-year-old women who carry BRCA1 or BRCA2 mutations gain from 2.9 to 5.3 years of life expectancy from prophylactic mastectomy and from 0.3 to 1.7 years of life expectancy from prophylactic oophorectomy, depending on their cumulative risk of cancer. Gains in life expectancy decline with age at the time of prophylactic surgery and are minimal for 60-year-old women. Among 30-year-old women, oophorectomy may be delayed 10 years with little loss of life expectancy. CONCLUSIONS: On the basis of a range of estimates of the incidence of cancer, prognosis, and efficacy of prophylactic surgery, our model suggests that prophylactic mastectomy provides substantial gains in life expectancy and prophylactic oophorectomy more limited gains for young women with BRCA1 or BRCA2 mutations.
|
Authors | D Schrag, K M Kuntz, J E Garber, J C Weeks |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 336
Issue 20
Pg. 1465-71
(May 15 1997)
ISSN: 0028-4793 [Print] United States |
PMID | 9148160
(Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- BRCA2 Protein
- Neoplasm Proteins
- Transcription Factors
|
Topics |
- Adult
- BRCA2 Protein
- Breast Neoplasms
(genetics, prevention & control)
- Decision Support Techniques
- Female
- Genes, BRCA1
- Humans
- Life Expectancy
- Mastectomy
- Middle Aged
- Mutation
- Neoplasm Proteins
(genetics)
- Ovarian Neoplasms
(genetics, prevention & control)
- Ovariectomy
- Primary Prevention
- Probability
- Transcription Factors
(genetics)
|